Last reviewed · How we verify
Lilly Bamlanivimab
Lilly Bamlanivimab is a Biologic drug developed by Erin McCreary. It is currently FDA-approved.
At a glance
| Generic name | Lilly Bamlanivimab |
|---|---|
| Sponsor | Erin McCreary |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- UPMC OPTIMISE-C19 Trial, a COVID-19 Study (PHASE4)
- A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Preventing SARS-CoV-2 Infection and COVID-19 in Nursing Home Residents and Staff (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lilly Bamlanivimab CI brief — competitive landscape report
- Lilly Bamlanivimab updates RSS · CI watch RSS
- Erin McCreary portfolio CI
Frequently asked questions about Lilly Bamlanivimab
What is Lilly Bamlanivimab?
Lilly Bamlanivimab is a Biologic drug developed by Erin McCreary.
Who makes Lilly Bamlanivimab?
Lilly Bamlanivimab is developed and marketed by Erin McCreary (see full Erin McCreary pipeline at /company/erin-mccreary).
What development phase is Lilly Bamlanivimab in?
Lilly Bamlanivimab is FDA-approved (marketed).
Related
- Manufacturer: Erin McCreary — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing